Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer

• Status: Not yet recruiting
• Trial end date: 2028-07-31

Summary

This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab emtansine may work better compared to usual treatment of chemotherapy with docetaxel and trastuzumab in treating patients with salivary gland cancer.

• Phase: Phase 2

Details

• Lead Sponsor: NRG Oncology
• Collaborator: National Cancer Institute (NCI)
• Treatments: Ado-Trastuzumab Emtansine; Antibodies; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Docetaxel; Immunoconjugates; Immunoglobulins; Maytansine; Trastuzumab; Trastuzumab biosimilar HLX02